Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
January 28, 2016
http://www.marketwired.com/press-release/small-cap-biotech-with-big-ideas-acute-infections-cancers-cellceutixs-leo-ehrlich-dr-2092183.htm
Search on Biofilm and you will get your answer. BP(JNJ:):):)) requested a 2nd batch of Brilacidin for testing.....
Kevetrin trial site.
Yesterdays update on clinicaltrials.gov gave it away...
https://www.marycrowley.org/clinical-trials/17-02/
Update: We now have 17 sites for B-OM and 33 Sites for Prurisol
https://clinicaltrials.gov/ct2/results?term=cellceutix&Search=Search
Pete I agree %1000. Nobody can place a true value on B with it's MASSIVE potential.
I think the 1st partnership will be a monster.
I think we see B-UP for Anti-Inflammatory and B-ABSSSI antibiotic in a packaged deal.
Ziagen normal dosage for HIV was 600mg.
Prurisol was dosed at 350 mg in the crossover study and Ziagen 300mg.
Otezla US patent expires 2024. Prurisol patent expires 2029....could be 2034-2036 because of 505 designation.
I don't think Celgene is a buyer here nor will Leo sell it to them just so they can put it on the shelf to save Otezla sales. Not Leo's style...
Look for 1 of the biologic companies to purchase Prurisol.
Mako wants us to contact the BOD and demand a R/S....
LMFAO!!!
These guys know they are toast.....
Petemantx Did UP or OM have a phase1?
ShEEEEEEEESH!
Cabel Leo is not running these drugs through a phase2 to accept any reasonable deal or get a single hit deal.
He wants a MONSTER deal and will get it.
It was spelled out when they talked about the $690M potential payout for that pre-clinical ibb drug if it ever got through phase2. Well like Leo/Art said "we are already there"
Completed Phase2 deals are triples or homerun's and we've got 5 of them by eoy.
UP done in 3 weeks. Then the fun starts and the FUD stops.
I thinks its obvious after the CC that IPIX will be making deals for each indication of Brilacidin. Since they have only "scratched" the surface of B's potential there is no way to determine fair value for an outright sale.
A deal for each indication is the way to go. The Regeneron way...
1st IPIX deal will be for UP(billion+ then followed by P(Billions) then OM(Billion +) then K(undetermined) then ABSSSI(out right sale for Billions).
Deals for UP and P this year and OM/K early 2018. Absssi late 2018.
NOT A BETTER STOCK TO OWN!!!
TIC TOC KABOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOM!!!!
"We are also making headway with our Kevetrin asset, which has shown potent anti-tumor activity. Following our Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, we are now preparing for a Phase 2a trial of Kevetrin for treating late stage ovarian cancer. We anticipate that this trial will start in the fourth quarter of this year. Our plan is to conduct a small trial that will provide the critical data necessary to forge a partnership with a large pharmaceutical company that could potentially fund development of Kevetrin through FDA approval. We are encouraged by the guidance and feedback that we have received from potential partners which are incorporated in our Phase 2a trial design."
Bait my butt. BP DEMANDED a Kevetrin ONLY POC trial
for a deal. BP:Show me K works mono and you have deal...
Great Pre clinical data that looked like a can't miss?
Really? Never made it thru Phase1? Really? Futility Really?
Know what you own and I know what I own.... currently 3 kick ass Phase2 trials running!!! 1 phase2b completed with kick ass results.
time will tell on k-oc...
Leo turning up the heat.................
We now have 31 Prurisol trial sites...
https://clinicaltrials.gov/ct2/show/NCT02949388?term=cellceutix&rank=5
Another Psoriasis Article on Website blog.
Why is Leo wasting his time posting these articles and adding clinical sites?
BECAUSE HE ALREADY KNOWS IT IS KICKING BUTT!!!!!!!!!!!!!!!!!!!!!!!!!!
TIC TOC KABOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOM!
http://www.cellceutix.com/new-blog/2017/1/18/celebrities-helping-to-raise-awareness-of-psoriasis
I agree. Get deals for EVERY indication with nice royalties for each indication then sell the Royalties. Kind of like PCYC selling their 50% royalty on Imbruvica for $21B I believe....
Like I said 6 months ago......
runninggirl2016 Saturday, 12/10/16 07:14:57 PM
Re: None
Post #
165651
of 183475 Go
SGX942 is NOT a prevention as B-OM is intended.
It just cuts the time in 1/2 that patients suffer with OM.
SGX942 successfully reduced the median duration of severe OM by 50% in all patients and by 67% in patients at highest risk of developing severe OM.
Not even a competitor if B-OM results are good.
B-OM will dominate the market due to it's
PREVENTATIVE property. NO OM drug approved or in clinical studies can claim that!
a 5 STAR restaurant
1 B-OM
2 B-UP
3 B-absssi
4 Prurisol Psoriasis
5 Kevetrin Ovarian
I bet we get an update in a PR just before the CC on those 11 OM patients who will be done dosing by next week. Results on 30+ Patients will open some eyes!!
TIC TOC KABOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOM!!!
GAME IS OVER FOR SHORTS!!!
If P pans out you want be able to buy Prurisol for $6B
let alone the ENTIRE company!!!
Overview from Cellceutix Website Blog 5/13/2017
https://static1.squarespace.com/static/5715352e20c647639137f992/t/59175fc01b10e3f7ad1b048d/1494704069303/2017+May+CTIX+Corporate+Overview.pdf
Didn't realize that B-OM was dosed only twice a week for 7 weeks. Thought it was everyday. Another little plus.
We now have 29 sites recruiting for Prurisol.
https://clinicaltrials.gov/ct2/show/study/NCT02949388?term=cellceutix&rank=5&show_locs=Y#locn
George I believe Arthur said the UP trial was about at the midway point during the presentation on 4/20. So 3 patients down and 3 to go as of 4/20...TIC TOC
KABOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO!
We are doing a 6 week P interim analysis for ONE reason.
...BIG PHARMA!!!
Kevetrin WAY ahead of the game....
https://medicalxpress.com/news/2017-05-elephants-cancer.html
Well we now know Aruda wasn't selling and Aspire would have to sell at a loss so it wasn't them. Who could it be? It couldn't be MM's selling invisible shares to themselves could it?
I mean with Bids of .69122222222222222 and Asks of .691222222222222223
That's normal right?
It was nice of Leo to Ask Aruda and even nicer for Aruda to file that 13g.
It has the FUDsters scrambling. Nice work LEO!!!
TIC TOC KABOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOM!
THE SHORTS DEFINITELY KNOW IT NOW!!!!!
Just10-12
$300,000,000 is over $100,000,000
$40+ by EOY.
Ah don't forget Breakthrough Therapy Designation for B-OM.
With no other prevention drugs even in clinical trials for OM,especially with NO sae's and is just a rinse and spit!!!!
B-OM is a slam dunk for BTD and QUICK...I MEAN QUICK APPROVAL!!. GAME OVER FOR SHORTS!
Noretreat seriously?
Quote:
I like how the talk was about "22.2%", when in fact it was 2 (two!) out of 9 TOTAL in the arm. 2 out of nine! that is never a "result".
How about 7 out of 9(77.7%) did NOT get Severe Oral Mucositis due to the Pro-Inflammatory property of Brilacidin.
2 out of 9( your 22.2%) did get it but it only lasted an average of 10.5 days for those 2 patients due to the ANTI-Inflammatory property of Brilacidin.
Those are RESULTS!
Brilacidin PRO-Inflammatory and ANTI-Inflammatory
HUGE!!!!!!!!!!!!!!!!!!!
and CTIX would only be worth 5-10 bucks?
"Prurisol alone would be safely in the 2-3B mark going into phase 3--and in my belief big pharma would likely slap down 200M upfront with 3B in structure on the backend"
A little hint on the Cellceutix site:)
Something must be going well just as I said yesterday.
Bet some people get a knot in their stomach.
1st time we've heard the word Prurisol in 5 months...hmmmm
http://www.cellceutix.com/new-blog/2016/10/5/leveraging-the-benefits-of-the-505b2-drug-development-approach-1
Interim P data will announced at
CC. BUCKLE UP!!!
TIC TOC KABOOOOOOOOOOOOOOOOOOOOOOOOOM!!!!!!!!!!
I bet JNJ is THRILLED Leo is going to apply for "Breakthrough Designation"
That means they can just file some paper work and then use Brilacidin in their Medical Devices Unit as soon as OM is approved and of course after JNJ pays Cellceutix handsomely.
All JNJ needs is any kind of approval for B and they are good to use it..
TIC TOC KABOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOM!!!!
MAXDUD WOW!!!!!
80's? Really?
You must be expecting a MAJOR deal to happen this week.
Thanks for the heads up.
I knew you were long the whole time!
80'S JUST WOW. I'm speechless!!!!!!!!!!!!
GO MAX...
GO CTIX!!!
Interesting.....
Looks like BP wants to see what Kevetrin can do mono then what a 2nd drug will do......But what drug or drugs?
Cellceutix has initiated a Phase 2a trial of Kevetrin in platinum-resistant/refractory ovarian cancer. Patients will receive more frequent Kevetrin administration (3 times per week), escalating to higher dosing in the second cohort, and after trial completion will receive standard of care treatment
The Polyheist. This will go down as the GREATEST acquisition EVER.
Cellceutix Scoops Up Bankrupt PolyMedix
Cellceutix said today it won approval from the U.S. Bankruptcy Court for the District of Delaware to acquire substantially all assets of PolyMedix for just under $5 million, five months after the small molecule drug developer filed for liquidation of assets under Chapter 7 bankruptcy code.
Cellceutix agreed to pay $2.1 million cash plus 1.4 million shares of its stock, in a deal approved by the court on Sept. 4. That day, shares of Cellceutix closed at $1.93 a share, bringing the value of the stock component based on that day’s price to $2.702 million.
Among assets Cellceutix agreed to acquire were PolyMedix’ pipeline of nine compounds, and equipment at PolyMedix’ 25,000-square-foot headquarters and laboratory in Radnor, PA. The nine compounds include PolyMedix’ flagship drug candidate Brilacidin, a first-in-class defensin-mimetic antibiotic that has completed a Phase IIa clinical trial comparing the experimental drug to the Cubist Pharmaceuticals treatment Cubicin. The trial demonstrated safety, tolerability, and efficacy of Brilacidin in patients with acute bacterial skin and skin structure infections (ABSSSIs) caused by Staphylococcus aureus, according to Cellceutix.
“This is a transformational development for our company and shareholders; adding the assets of PolyMedix for a tiny fraction of what we believe the company is truly worth,” Cellceutix CEO Leo Ehrlich said in a statement. “We are very excited about instantly having a strong antibiotic franchise to complement our already robust pipeline that now contains 18 compounds.”
He said Cellceutix intends to quickly advance Brilacidin into a Phase IIb clinical trial, adding his company envisions the drug as a competitor to treatments in the category of Pfizer’s Zyvox, which generated $1.35 billion in sales in 2012.
Cellceutix has also shifted its development strategy with its experimental antipsoriasis drug Prurisol by foregoing a planned proof-of-concept trial overseas, instead preparing the regulatory paperwork for the FDA to initiate a larger-scale, Phase II/III multi-center trial. “The adjustment will save us hundreds of thousands of dollars and months of time that will now be better served to position us to potentially have up to five clinical trials ongoing in 2014,” Ehrlich said.
PolyMedix filed for Chapter 7 bankruptcy in April, after defaulting on a $6.8 million payment due to creditor MidCap Financial. At the time, Edward F. Smith resigned as the company’s acting president, CEO, and CFO. A year earlier, Polymedix could boast of 28 employees and a market capitalization of $227.4 million.
GREAT JOB LEO!!!!!!!!!!!!!!!!!!
Wonder if someone requested more patients
before signing on the dotted line. They are probably liking what 400mg is doing and want to see more of that dose:)
189 patients have certainly been enrolled. That would only require 2 patients enrolled per month per site for these 4 months which happens next Sunday the 9th.
Something BIG is happening with this trial.
Like I said before no way does Leo do a Private Placement for $2.2 million if the Prurisol trial isn't producing. That's a lawsuit for sure.
The $2.2 is definitely going to this trial.